Developer docs
API playgroundTry for free, no card

Search company profiles

ImCare Biotech

Full company profile

uuid0002yrd

Namestring
ImCare Biotech
Legal namestring
ImCare Biotech, Inc.
Company typeenum
Private
Founded yearint
2011
Descriptiontext

ImCare Biotech, Inc. is a privately held clinical-stage biotechnology company founded in 2011 by Dr. Xuanyong Lu, headquartered at the Pennsylvania Biotechnology Center in Doylestown, PA, with a core team of approximately four executives. The company is developing diagnostic and pharmaceutical products targeting liver cancer, anchored by the proprietary LC-SPIK (Liver Cancer-Specific Serine Protease Inhibitor Kazal) biomarker and its lead diagnostic product, the Seravue® ELISA kit. Seravue has received FDA Breakthrough Device Designation (June 2020) for the early detection of Hepatocellular Carcinoma (HCC), with clinical validation across 1,200+ patients showing 80% sensitivity and 90% specificity for all-stage HCC and 72%/90% for early-stage disease, materially outperforming the AFP standard of care. The company is also advancing drug discovery programs (IMB101, IMB102) and supporting technologies including Immune-absorbance Real-Time PCR (IA-PCR) and the Anti-SPINK1 antibody (BA1).

The business operates on a dual-track model. Today, revenue is generated primarily through direct e-commerce sales of Research Use Only (RUO) and cGMP-grade LC-SPIK ELISA kits ($499–$649 per kit) to academic, government, and non-profit research institutions via shop.imcarebiotech.com. Commercial clinical sales are gated on FDA clearance, after which the company plans to distribute Seravue to hospitals, healthcare providers, and clinical laboratories, with potential automatic Medicare coverage under the CMS MCIT pathway. Non-dilutive funding has been substantial: SBIR Phase I (2012), Phase II (2015), and a Phase IIB Bridge Award of up to $4M over three years (October 2021) from the National Cancer Institute, supplemented by SEC-registered equity raises totaling roughly $1.8M between 2020 and 2023.

The company's strategic positioning rests on a granted US patent (US8193328B2) covering SPIK modulators for anti-cancer and anti-viral use, a pending SPIK antibody patent application, registered Seravue® and LC-SPIK trademarks, and a network of academic co-development partnerships with Harvard Medical School, Drexel University, UC Irvine, Ohio State University, and Thomas Jefferson University. Leadership combines commercial expertise from CEO Aaron Yefei Lu (McKinsey, Stanford, London Business School) with scientific depth from President/Co-founder Xuanyong Lu and CSO Karteek Kadimisetty (PhD, UConn), supported by VP of Engineering Bobby Biswal leading software and AI development for diagnostic modeling.

Short descriptiontext

ImCare Biotech is a privately held Doylestown, PA biotech developing the Seravue® LC-SPIK ELISA diagnostic and companion drug compounds for early detection and treatment of hepatocellular carcinoma, serving academic researchers today and targeting clinical laboratories upon FDA clearance.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDoylestown, United States
HQ citystring
Doylestown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
liver cancer diagnostics, hepatocellular carcinoma detection, ELISA diagnostic kits, cancer biomarker research, biotechnology diagnostics
Industry3 codes
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Pharmaceutical Preparations2834
Product category
Cancer Diagnostics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Research Use Only (RUO) ELISA Kits
TypeHardware Sales
Description

Sale of research use only ELISA kits for LC-SPIK and AFP biomarker detection. Products sold directly through company's e-commerce platform to academic institutions, research organizations, and non-profit entities. Revenue is transaction-based with one-time purchases.

shop.imcarebiotech.com
2Diagnostic Products (Post-FDA Clearance)
TypeOne Time License
Description

Upon FDA clearance, Seravue diagnostic kit will be sold for clinical diagnostic use in HCC detection. Targeting healthcare providers, hospitals, and clinical laboratories. Future potential revenue from cGMP grade kits for enhanced applications.

imcarebiotech.com
3Government Grants (NIH/NCI)
TypeLicensing Royalties
Description

Non-dilutive funding through Small Business Innovation Research (SBIR) grants from National Cancer Institute/NIH. Includes Phase II grant and Phase IIB Bridge Award of up to $4M over three years for commercialization and pivotal clinical study support.

imcarebiotech.com
4Securities Offerings
TypeAffiliate Referral
Description

Private securities offerings under SEC Rule 506(b) for equity investment. Historical offerings: approximately $1.28M (2021), $368,415 (2022), $153,402 (2023) as per SEC Form D filings.

sec.gov
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
Pricing details3 tiers
1Human LC-SPIK ELISA Kit - Seravue® (Research Use Only)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$549.00 USD per kit. Sensitive enzyme-linked immunosorbent assay for quantification of human LC-SPIK levels in serum and plasma samples. For detecting hepatocellular carcinoma (HCC) in research settings.

shop.imcarebiotech.com
2Human LC-SPIK ELISA Kit - Seravue® (cGMP Grade)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$649.00 USD per kit. cGMP grade version for enhanced quality requirements. Includes 96-strip well microplate, calibrators, controls, detection antibody, and assay components.

shop.imcarebiotech.com
3Human AFP ELISA Kit (Research Use Only)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$499.00 USD per kit. ELISA for quantification of alpha-fetoprotein (AFP) levels in serum and plasma. Assists in HCC detection research.

shop.imcarebiotech.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Seravue
Description

The primary diagnostic product brand for ImCare Biotech's liver cancer detection test using the LC-SPIK biomarker. Available as ELISA kits for research use.

shop.imcarebiotech.com
Core offering1 text field

ImCare Biotech develops and sells ELISA-based diagnostic test kits (Seravue) that utilize its proprietary LC-SPIK (Liver Cancer-Specific Serine Protease Inhibitor Kazal) biomarker for detection of Hepatocellular Carcinoma (HCC). The kits are currently sold for research use only (RUO) to academic and research institutions, with a cGMP-grade variant also offered. The company is pursuing FDA clearance for clinical diagnostic use of Seravue.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • LC-SPIK AUC 0.87 with 80% sensitivity/90% specificity for all HCC vs AFP AUC 0.70 with 52% sensitivity/86% specificity
+5 more records
Product overview1 text field

ImCare Biotech is a biotechnology company focused on liver disease diagnostics and drug development. Its core commercial products are the Seravue® LC-SPIK ELISA Kit (available in RUO and cGMP-grade variants), an FDA Breakthrough Device-designated diagnostic blood test for hepatocellular carcinoma (HCC) based on the proprietary LC-SPIK biomarker, alongside the Human AFP ELISA Kit (RUO). The product portfolio is complemented by the Anti-SPINK1 Antibody (BA1) and the IA-PCR technology platform used internally for drug screening. In drug development, ImCare is advancing IMB101 and IMB102 as novel anti-cancer compounds targeting SPIK-mediated immune evasion. All products are for research use only and not yet approved for clinical diagnosis.

Product and service5 records
1Seravue Human LC-SPIK ELISA Kit (RUO)
CategoryDiagnostic Test Kit
Description

ELISA-based diagnostic test kit for quantification of human LC-SPIK levels in serum and plasma samples for the detection of Hepatocellular Carcinoma (HCC), including early-stage HCC. Sold for research use only to academic, government, and research organizations.

2Seravue Human LC-SPIK ELISA Kit (cGMP Grade)
CategoryDiagnostic Test Kit
Description

cGMP-grade variant of the LC-SPIK ELISA Kit with assay range 0.31-10.0 ng/mL and sensitivity approximately 0.05 ng/mL. Designed for enhanced quality requirements in research and product evaluation settings.

3Human AFP ELISA Kit (RUO)
CategoryDiagnostic Test Kit
Description

Research-use-only ELISA kit for the precise quantification of human Alpha-fetoprotein (AFP) levels in serum, plasma, and cellular media samples (assay range 0.25-16.0 ng/mL). Supports hepatocellular carcinoma detection research and multi-analyte biomarker panel testing.

4Anti-SPINK1 Antibody (BA1)
CategoryResearch Reagent
Description

Monoclonal antibody that recognizes native human pancreatic secreted SPINK1/TATI/PSTI in Western Blot and ELISA applications, supporting academic research on SPIK/LC-SPIK biology.

5IMB101 and IMB102 (Drug Compounds)
CategoryPharmaceutical Compound
Description

Anti-cancer drug compounds in development with IC50 of approximately 1µM and CC50 greater than 100µM in vitro. Designed to restore the immune system's ability to kill oncogenic cells by inhibiting SPIK activity.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Harvard Medical School
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-01-18
Description

Development partnership with Harvard Medical School representing high-profile academic collaboration. Contributed prestigious research validation and expertise to support diagnostic technology development.

imcarebiotech.com
2Ohio State University
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2014-07-18
Description

Development partnership for liver cancer diagnostic technology development. Ohio State University contributed research infrastructure and academic expertise.

imcarebiotech.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2014-01-18
Description

Development partnership established for collaborative research on liver disease diagnostics. Thomas Jefferson University contributed academic research capabilities and clinical expertise.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2012-05-18
Description

ImCare Biotech signed agreement with Drexel University's College of Medicine to develop Seravue diagnostic technology. This partnership contributed to the foundational development of the LC-SPIK biomarker technology and Seravue ELISA test for early liver cancer detection.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2012-05-18
Description

Collaborated with UC Irvine Medical Center alongside Drexel University for Seravue development. Contributed clinical expertise and resources to support diagnostic kit development for liver cancer detection.

6South-Central University for Nationalities (China)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2011-11-18
Description

Strategic cooperation signed in November 2011 for collaborative research activities related to liver disease diagnostics and treatment development.

imcarebiotech.com
7Hubei Cancer Hospital
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2011-11-18
Description

Strategic cooperation with Hubei Cancer Hospital in China for liver cancer research and diagnostic development collaboration.

imcarebiotech.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developer of Oncoguard Liver, a blood-based multi-analyte HCC surveillance test in advanced clinical development. Directly comparable to ImCare's Seravue as a competing biomarker-based HCC detection assay targeting at-risk surveillance populations.

TypeBroad incumbent
Description

Major supplier of ELISA kits, antibodies, and reagents to academic and translational researchers, including cancer biomarker research. Comparable to ImCare's RUO ELISA kit business as a reagent/research-tools incumbent.

TypeBroad incumbent
Description

Global supplier of research-use-only antibodies, ELISA kits, and assay reagents, including cancer biomarker products. Comparable to ImCare's RUO kit and Anti-SPINK1 antibody (BA1) product lines as a much larger reagent incumbent.

TypeBroad incumbent
Description

Sells Elecsys AFP and other clinical chemistry assays including PIVKA-II/DCP used in HCC detection. Indirectly competes with Seravue as part of a broad clinical diagnostics portfolio across hospital and reference laboratory channels.

TypeEmerging player
Description

Developer of Signatera tumor-informed molecular residual disease and early cancer detection tests. Comparable as a blood-based cancer diagnostics peer pursuing novel biomarker approaches, though at significantly larger scale.

6Abbott Diagnostics
TypeBroad incumbent
Description

Manufacturer of ARCHITECT AFP and other immunoassays routinely used in HCC workups. Comparable as a large incumbent with established clinical laboratory distribution that any new HCC biomarker would need to displace or complement.

TypeEmerging player
Description

Clinical-stage diagnostics company developing blood-based nucleosome biomarker tests for cancer detection. Comparable as a small-cap, pre-commercialization cancer diagnostics peer pursuing multi-cancer detection through novel blood-based biomarkers.

TypeEmerging player
Description

Developer of liquid biopsy tests for cancer detection and monitoring, with potential applicability to HCC. Comparable as a blood-based cancer diagnostics peer though operating at significantly larger scale and broader cancer focus.

9EDP Biotech
TypeDirect peer
Description

Small-cap diagnostics company developing blood-based biomarker tests for early cancer detection, including HCC. Comparable to ImCare as a similarly sized, single-asset-focused liver cancer diagnostics developer.

TypeBroad incumbent
Description

Specializes in clinical immunoassays including liver cancer biomarker tests (e.g., AFP-L3, DCP). Comparable as an established specialty diagnostics company with regulatory-cleared HCC biomarker products globally.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ImCare Biotech

Cancer Diagnosticsimcarebiotech.com

ImCare Biotech is a privately held Doylestown, PA biotech developing the Seravue® LC-SPIK ELISA diagnostic and companion drug compounds for early detection and treatment of hepatocellular carcinoma, serving academic researchers today and targeting clinical laboratories upon FDA clearance.

What ImCare Biotech does

ImCare Biotech, Inc. is a privately held clinical-stage biotechnology company founded in 2011 by Dr. Xuanyong Lu, headquartered at the Pennsylvania Biotechnology Center in Doylestown, PA, with a core team of approximately four executives. The company is developing diagnostic and pharmaceutical products targeting liver cancer, anchored by the proprietary LC-SPIK (Liver Cancer-Specific Serine Protease Inhibitor Kazal) biomarker and its lead diagnostic product, the Seravue® ELISA kit. Seravue has received FDA Breakthrough Device Designation (June 2020) for the early detection of Hepatocellular Carcinoma (HCC), with clinical validation across 1,200+ patients showing 80% sensitivity and 90% specificity for all-stage HCC and 72%/90% for early-stage disease, materially outperforming the AFP standard of care. The company is also advancing drug discovery programs (IMB101, IMB102) and supporting technologies including Immune-absorbance Real-Time PCR (IA-PCR) and the Anti-SPINK1 antibody (BA1).

The business operates on a dual-track model. Today, revenue is generated primarily through direct e-commerce sales of Research Use Only (RUO) and cGMP-grade LC-SPIK ELISA kits ($499–$649 per kit) to academic, government, and non-profit research institutions via shop.imcarebiotech.com. Commercial clinical sales are gated on FDA clearance, after which the company plans to distribute Seravue to hospitals, healthcare providers, and clinical laboratories, with potential automatic Medicare coverage under the CMS MCIT pathway. Non-dilutive funding has been substantial: SBIR Phase I (2012), Phase II (2015), and a Phase IIB Bridge Award of up to $4M over three years (October 2021) from the National Cancer Institute, supplemented by SEC-registered equity raises totaling roughly $1.8M between 2020 and 2023.

The company's strategic positioning rests on a granted US patent (US8193328B2) covering SPIK modulators for anti-cancer and anti-viral use, a pending SPIK antibody patent application, registered Seravue® and LC-SPIK trademarks, and a network of academic co-development partnerships with Harvard Medical School, Drexel University, UC Irvine, Ohio State University, and Thomas Jefferson University. Leadership combines commercial expertise from CEO Aaron Yefei Lu (McKinsey, Stanford, London Business School) with scientific depth from President/Co-founder Xuanyong Lu and CSO Karteek Kadimisetty (PhD, UConn), supported by VP of Engineering Bobby Biswal leading software and AI development for diagnostic modeling.

ImCare Biotech firmographics

Firmographics
Name
ImCare Biotech
Legal name
ImCare Biotech, Inc.
Website
https://imcarebiotech.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
ImCare Biotech is a privately held Doylestown, PA biotech developing the Seravue® LC-SPIK ELISA diagnostic and companion drug compounds for early detection and treatment of hepatocellular carcinoma, serving academic researchers today and targeting clinical laboratories upon FDA clearance.
Ownership category
akta.pro rank

ImCare Biotech industry classification

Industry
Product category
Cancer Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Pharmaceutical Preparation Manufacturing (325412)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Liver cancer diagnostics
  • Hepatocellular carcinoma detection
  • ELISA diagnostic kits
  • Cancer biomarker research
  • Biotechnology diagnostics

Where ImCare Biotech is headquartered

Location

Headquarters

HQ city
Doylestown
HQ country
United States
HQ region
North America

Offices1 record

Markets served

ImCare Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Research Use Only (RUO) ELISA Kits: Sale of research use only ELISA kits for LC-SPIK and AFP biomarker detection. Products sold directly through company's e-commerce platform to academic institutions, research organizations, and non-profit entities. Revenue is transaction-based with one-time purchases.
  2. Diagnostic Products (Post-FDA Clearance): Upon FDA clearance, Seravue diagnostic kit will be sold for clinical diagnostic use in HCC detection. Targeting healthcare providers, hospitals, and clinical laboratories. Future potential revenue from cGMP grade kits for enhanced applications.
  3. Government Grants (NIH/NCI): Non-dilutive funding through Small Business Innovation Research (SBIR) grants from National Cancer Institute/NIH. Includes Phase II grant and Phase IIB Bridge Award of up to $4M over three years for commercialization and pivotal clinical study support.
  4. Securities Offerings: Private securities offerings under SEC Rule 506(b) for equity investment. Historical offerings: approximately $1.28M (2021), $368,415 (2022), $153,402 (2023) as per SEC Form D filings.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goHuman LC-SPIK ELISA Kit - Seravue® (Research Use Only)
Unit PricingPay-as-you-goHuman LC-SPIK ELISA Kit - Seravue® (cGMP Grade)
Unit PricingPay-as-you-goHuman AFP ELISA Kit (Research Use Only)

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

ImCare Biotech product offering

Product offering

Core offering

ImCare Biotech develops and sells ELISA-based diagnostic test kits (Seravue) that utilize its proprietary LC-SPIK (Liver Cancer-Specific Serine Protease Inhibitor Kazal) biomarker for detection of Hepatocellular Carcinoma (HCC). The kits are currently sold for research use only (RUO) to academic and research institutions, with a cGMP-grade variant also offered. The company is pursuing FDA clearance for clinical diagnostic use of Seravue.

Product overview

ImCare Biotech is a biotechnology company focused on liver disease diagnostics and drug development. Its core commercial products are the Seravue® LC-SPIK ELISA Kit (available in RUO and cGMP-grade variants), an FDA Breakthrough Device-designated diagnostic blood test for hepatocellular carcinoma (HCC) based on the proprietary LC-SPIK biomarker, alongside the Human AFP ELISA Kit (RUO). The product portfolio is complemented by the Anti-SPINK1 Antibody (BA1) and the IA-PCR technology platform used internally for drug screening. In drug development, ImCare is advancing IMB101 and IMB102 as novel anti-cancer compounds targeting SPIK-mediated immune evasion. All products are for research use only and not yet approved for clinical diagnosis.

Differentiator

Problem solved

Functional benefit

Brands

  • Seravue: The primary diagnostic product brand for ImCare Biotech's liver cancer detection test using the LC-SPIK biomarker. Available as ELISA kits for research use.

Products and services

  • Seravue Human LC-SPIK ELISA Kit (RUO) ELISA-based diagnostic test kit for quantification of human LC-SPIK levels in serum and plasma samples for the detection of Hepatocellular Carcinoma (HCC), including early-stage HCC. Sold for research use only to academic, government, and research organizations.
  • Seravue Human LC-SPIK ELISA Kit (cGMP Grade) cGMP-grade variant of the LC-SPIK ELISA Kit with assay range 0.31-10.0 ng/mL and sensitivity approximately 0.05 ng/mL. Designed for enhanced quality requirements in research and product evaluation settings.
  • Human AFP ELISA Kit (RUO) Research-use-only ELISA kit for the precise quantification of human Alpha-fetoprotein (AFP) levels in serum, plasma, and cellular media samples (assay range 0.25-16.0 ng/mL). Supports hepatocellular carcinoma detection research and multi-analyte biomarker panel testing.
  • Anti-SPINK1 Antibody (BA1) Monoclonal antibody that recognizes native human pancreatic secreted SPINK1/TATI/PSTI in Western Blot and ELISA applications, supporting academic research on SPIK/LC-SPIK biology.
  • IMB101 and IMB102 (Drug Compounds) Anti-cancer drug compounds in development with IC50 of approximately 1µM and CC50 greater than 100µM in vitro. Designed to restore the immune system's ability to kill oncogenic cells by inhibiting SPIK activity.

Quantifiable outcome

  • LC-SPIK AUC 0.87 with 80% sensitivity/90% specificity for all HCC vs AFP AUC 0.70 with 52% sensitivity/86% specificity
  • +5 more outcomes

Companies that use ImCare Biotech

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

ImCare Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

ImCare Biotech partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Harvard Medical SchoolcoreStrategic or Co-development Partner · 18 January 2015Development partnership with Harvard Medical School representing high-profile academic collaboration. Contributed prestigious research validation and expertise to support diagnostic technology development.
  • Ohio State UniversitycoreStrategic or Co-development Partner · 18 July 2014Development partnership for liver cancer diagnostic technology development. Ohio State University contributed research infrastructure and academic expertise.
  • Thomas Jefferson UniversitycoreStrategic or Co-development Partner · 18 January 2014Development partnership established for collaborative research on liver disease diagnostics. Thomas Jefferson University contributed academic research capabilities and clinical expertise.
  • Drexel University, College of MedicinecoreStrategic or Co-development Partner · 18 May 2012ImCare Biotech signed agreement with Drexel University's College of Medicine to develop Seravue diagnostic technology. This partnership contributed to the foundational development of the LC-SPIK biomarker technology and Seravue ELISA test for early liver cancer detection.
  • University of California, Irvine, Medical CentercoreStrategic or Co-development Partner · 18 May 2012Collaborated with UC Irvine Medical Center alongside Drexel University for Seravue development. Contributed clinical expertise and resources to support diagnostic kit development for liver cancer detection.
  • South-Central University for Nationalities (China)minorStrategic or Co-development Partner · 18 November 2011Strategic cooperation signed in November 2011 for collaborative research activities related to liver disease diagnostics and treatment development.
  • Hubei Cancer HospitalminorStrategic or Co-development Partner · 18 November 2011Strategic cooperation with Hubei Cancer Hospital in China for liver cancer research and diagnostic development collaboration.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

ImCare Biotech competitors and assessment

Company assessment

Direct peers

  • Exact Sciences: Developer of Oncoguard Liver, a blood-based multi-analyte HCC surveillance test in advanced clinical development. Directly comparable to ImCare's Seravue as a competing biomarker-based HCC detection assay targeting at-risk surveillance populations.
  • EDP Biotech: Small-cap diagnostics company developing blood-based biomarker tests for early cancer detection, including HCC. Comparable to ImCare as a similarly sized, single-asset-focused liver cancer diagnostics developer.

Broad incumbents

  • Bio-Techne: Major supplier of ELISA kits, antibodies, and reagents to academic and translational researchers, including cancer biomarker research. Comparable to ImCare's RUO ELISA kit business as a reagent/research-tools incumbent.
  • Abcam: Global supplier of research-use-only antibodies, ELISA kits, and assay reagents, including cancer biomarker products. Comparable to ImCare's RUO kit and Anti-SPINK1 antibody (BA1) product lines as a much larger reagent incumbent.
  • Roche Diagnostics: Sells Elecsys AFP and other clinical chemistry assays including PIVKA-II/DCP used in HCC detection. Indirectly competes with Seravue as part of a broad clinical diagnostics portfolio across hospital and reference laboratory channels.
  • Abbott Diagnostics: Manufacturer of ARCHITECT AFP and other immunoassays routinely used in HCC workups. Comparable as a large incumbent with established clinical laboratory distribution that any new HCC biomarker would need to displace or complement.
  • Fujirebio Diagnostics: Specializes in clinical immunoassays including liver cancer biomarker tests (e.g., AFP-L3, DCP). Comparable as an established specialty diagnostics company with regulatory-cleared HCC biomarker products globally.

Emerging players

  • Natera: Developer of Signatera tumor-informed molecular residual disease and early cancer detection tests. Comparable as a blood-based cancer diagnostics peer pursuing novel biomarker approaches, though at significantly larger scale.
  • VolitionRx: Clinical-stage diagnostics company developing blood-based nucleosome biomarker tests for cancer detection. Comparable as a small-cap, pre-commercialization cancer diagnostics peer pursuing multi-cancer detection through novel blood-based biomarkers.
  • Guardant Health: Developer of liquid biopsy tests for cancer detection and monitoring, with potential applicability to HCC. Comparable as a blood-based cancer diagnostics peer though operating at significantly larger scale and broader cancer focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

ImCare Biotech social profiles

Digital presence

ImCare Biotech compliance and trust

Trust signal

Compliance2 records

ImCare Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ImCare Biotech leadership team

Management profile

Number of profiles

Profiles4 records

ImCare Biotech funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ImCare Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ImCare Biotech

What does ImCare Biotech do?

ImCare Biotech develops and sells ELISA-based diagnostic test kits (Seravue) that utilize its proprietary LC-SPIK (Liver Cancer-Specific Serine Protease Inhibitor Kazal) biomarker for detection of Hepatocellular Carcinoma (HCC). The kits are currently sold for research use only (RUO) to academic and research institutions, with a cGMP-grade variant also offered. The company is pursuing FDA clearance for clinical diagnostic use of Seravue.

Is ImCare Biotech a public or private company?

ImCare Biotech is a private company. It is classified as venture growth investor backed and is currently operating.

When was ImCare Biotech founded?

ImCare Biotech was founded in 2011. It employs 11 to 50 people.

Where is ImCare Biotech based?

ImCare Biotech is headquartered in Doylestown, United States, in the North America region.

How does ImCare Biotech make money?

Four revenue lines are on record. Research Use Only (RUO) ELISA Kits are the primary driver. The others are diagnostic Products (Post-FDA Clearance), government Grants (NIH/NCI) and securities Offerings.

Who are ImCare Biotech's main competitors?

Direct peers on record are Exact Sciences and EDP Biotech. Broad incumbents are Bio-Techne, Abcam, Roche Diagnostics, Abbott Diagnostics and Fujirebio Diagnostics. Emerging players are Natera, VolitionRx and Guardant Health.

Does ImCare Biotech have an API?

No public API is recorded for ImCare Biotech.

What industry is ImCare Biotech in?

ImCare Biotech's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes), with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals